2 results match your criteria: "The General Surgery Department of The Second Hospital of Anhui Medical University[Affiliation]"
SPHK1 promotes HNSCC immune evasion by regulating the MMP1-PD-L1 axis.
Theranostics
December 2024
Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, Guangdong, People's Republic of China.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) show promise in treating head and neck squamous cell carcinoma (HNSCC), but their effectiveness is limited, necessitating further research.
- The study investigates the role of sphingosine kinase 1 (SPHK1) in HNSCC, finding it enhances tumor growth by suppressing the immune response and promotes immune evasion through regulation of matrix metalloproteinase-1 (MMP1) and PD-L1 expression.
- SPHK1 and MMP1 were identified as potential biomarkers for predicting responses to PD-1 monoclonal antibody immunotherapy and serve as independent risk factors for patient survival in HNSCC.
Background: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer.
View Article and Find Full Text PDF